Bexarotene monotherapy for patients with refractory early stage mycosis fungoides.
Stein
Annette
A
Department of Dermatology, University Hospital Carl Gustav Carus Dresden, University of Technology, Dresden, Germany. Annette.Stein@uniklinikum-dresden.de
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020521:Stroke; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene